Warning: The NCBI web site requires JavaScript to function. more...
mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer.
Cheng C, Fu X, Alves P, Gerstein M.
Genome Biol. 2009;10(9):R90. Epub 2009 Sep 1.
Related citations
Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.
Smith DD, Saetrom P, Snøve O Jr, Lundberg C, Rivas GE, Glackin C, Larson GP.
BMC Bioinformatics. 2008 Jan 28;9:63.
Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ.
PLoS One. 2009;4(3):e4710. Epub 2009 Mar 9.
Challenges in projecting clustering results across gene expression-profiling datasets.
Lusa L, McShane LM, Reid JF, De Cecco L, Ambrogi F, Biganzoli E, Gariboldi M, Pierotti MA.
J Natl Cancer Inst. 2007 Nov 21;99(22):1715-23. Epub 2007 Nov 13.
The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer.
Calaluce R, Gubin MM, Davis JW, Magee JD, Chen J, Kuwano Y, Gorospe M, Atasoy U.
BMC Cancer. 2010 Apr 6;10:126.
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.
Breast Cancer Res. 2009;11(3):R27. Epub 2009 May 11.
Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
Yau C, Benz CC.
Breast Cancer Res. 2008;10(4):R61. Epub 2008 Jul 17.
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, Chew K, Dairkee SH, Moore DH, Schittulli F, Tommasi S, Paradiso A, Albertson DG, Benz CC.
Breast Cancer Res. 2007;9(5):R59.
microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer.
Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J.
Cancer Res. 2011 Sep 1;71(17):5635-45. Epub 2011 Jul 7.
MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer.
Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK.
Horm Cancer. 2010 Dec;1(6):306-19.
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.
Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C.
Mol Cancer. 2006 Jun 19;5:24.
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.
Breast Cancer Res. 2009;11(2):R15. Epub 2009 Mar 9.
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells.
Lin CY, Ström A, Vega VB, Kong SL, Yeo AL, Thomsen JS, Chan WC, Doray B, Bangarusamy DK, Ramasamy A, Vergara LA, Tang S, Chong A, Bajic VB, Miller LD, Gustafsson JA, Liu ET.
Genome Biol. 2004;5(9):R66. Epub 2004 Aug 12.
Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray.
Nagahata T, Onda M, Emi M, Nagai H, Tsumagari K, Fujimoto T, Hirano A, Sato T, Nishikawa K, Akiyama F, Sakamoto G, Kasumi F, Miki Y, Tanaka T, Tsunoda T.
Cancer Sci. 2004 Mar;95(3):218-25.
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF.
Clin Cancer Res. 2003 Jul;9(7):2406-15.
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.
Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA.
Genome Biol. 2007;8(10):R214.
Estradiol-regulated microRNAs control estradiol response in breast cancer cells.
Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, Brown M, Hammond S, Srour EF, Liu Y, Nakshatri H.
Nucleic Acids Res. 2009 Aug;37(14):4850-61. Epub 2009 Jun 14.
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells.
Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM.
Nucleic Acids Res. 2009 May;37(8):2584-95. Epub 2009 Mar 5.
18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, Cook JB, Larson S.
J Nucl Med. 2010 Apr;51(4):543-50. Epub 2010 Mar 17.
Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer.
Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR, Xiao GG.
Breast Cancer Res Treat. 2011 May;127(1):69-80. Epub 2010 Jun 10.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on